Nordea Investment Management AB Purchases 1,633 Shares of Illumina, Inc. $ILMN

Nordea Investment Management AB grew its position in Illumina, Inc. (NASDAQ:ILMN) by 14.2% in the second quarter, Holdings Channel reports. The fund owned 13,138 shares of the life sciences company’s stock after acquiring an additional 1,633 shares during the quarter. Nordea Investment Management AB’s holdings in Illumina were worth $1,265,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. WCM Investment Management LLC lifted its stake in shares of Illumina by 5.9% in the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after acquiring an additional 247,460 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its stake in shares of Illumina by 36.6% in the 2nd quarter. Wilmington Savings Fund Society FSB now owns 8,194 shares of the life sciences company’s stock valued at $782,000 after acquiring an additional 2,194 shares during the last quarter. RFG Advisory LLC lifted its stake in shares of Illumina by 39.1% in the 2nd quarter. RFG Advisory LLC now owns 5,411 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 1,520 shares during the last quarter. NorthRock Partners LLC bought a new position in shares of Illumina in the 2nd quarter valued at $585,000. Finally, Envestnet Portfolio Solutions Inc. raised its position in Illumina by 0.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after purchasing an additional 99 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of Illumina stock opened at $99.97 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $98.17 and a two-hundred day moving average price of $91.30. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a market cap of $15.37 billion, a P/E ratio of 12.65, a PEG ratio of 2.40 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business posted $0.36 EPS. The business’s revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Evercore ISI lowered their target price on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Citigroup lowered Illumina from a “hold” rating to a “strong sell” rating and lowered their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays raised their target price on Illumina from $90.00 to $95.00 and gave the stock an “underweight” rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.